DURECT Corp.'s CEO James E. Brown Interviewed by The Life

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
DURECT Corp.'s CEO James E. Brown Interviewed by The Life Sciences Report

SAN FRANCISCO, CA --(Marketwired - February 02, 2016) - Alza Corp. was a pioneer in the field of drug delivery, and that illustrious heritage continues in its spinout, DURECT Corp.  ( NASDAQ : DRRX ), which has leveraged the technology to enable highly innovative, value-added products that may soon be on the market. In this interview with The Life Sciences Report , DURECT cofounder and CEO James E. Brown discusses his company's pipeline, and how DURECT is evolving into a high-margin, blockbuster biotech.

The Life Sciences Report:  Jim, you helped found DURECT Corp. back in 1998. It was spun out of Alza Corp. (acquired by Johnson & Johnson in 2001), a pioneer in the field of drug delivery formulations. You went public in 2000, and have endured a lot of market cycles through the years. As we speak, the capital markets are in the throes of global volatility resulting from a confluence of factors including the disturbing selloff in China, North Korea detonating an atomic bomb, diplomatic unrest between Saudi Arabia and Iran, and the U.S. Federal Reserve signaling it will continue to raise short-term interest rates. What have you learned about holding a business together during this kind of disruption?

JB : My experience in biopharma tells me that a company like DURECT is somewhat divorced from the hiccups occurring in China or in the broader economy. I'm not focused on anything but moving our pipeline along and bringing meaningful new drugs to the marketplace. If we do that successfully, then we're going to be successful for both shareholders and patients. In 2016 we have the potential to see our very first product come to market. This turmoil is a tough way to start the new year, for sure, but the U.S. and European economies seem to be in good shape.

Once things settle down, as they always do, it seems to me investors will come to realize that our sector, biopharmaceuticals, is a wonderful place to invest. This sector is the place to be because...

Continue reading this interview: Making Old Drugs New Again with Specialized Biotech: DURECT Corp.'s James E. Brown

About Streetwise Reports -  The Life Sciences Report

Investors rely on The Life Sciences Report to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. Our exclusive interviews with leading industry experts and analysts provide a clear picture of the causes of macro-economic shifts and the strategies that help you capitalize on developing trends.

DISCLOSURE:

DURECT Corp. is a sponsor of Streetwise Reports. Dr. James E. Brown had final approval of the content and is wholly responsible for the validity of the statements. Opinions expressed are the opinions of Dr. Brown and not of The Life Sciences Report or its officers. The interview does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility.

Please see Streetwise Reports' terms of use and full legal disclaimer .

Carrie Beal Amaro Email contact

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fall Pest Risks Linger as Mild Weather Extends Threat

Updated Category News Views 125

A cold snap is not a magic off switch for mosquitoes, ticks, or rodents, and that is the sober point behind the National Pest Management Association's fall and winter 2026 Public Health Pest Index. The group is flagging conditions, not predicting that every household in a named city will face an infestation or illness. Still, mild temperatures, rain, flooding, and plenty...

Continue Reading
Thanksgiving AI Talk Needs Better Safety Questions

Updated Category News Views 0

Thanksgiving has somehow acquired a new household hazard: somebody casually pasting private information into a chatbot between football and dessert. SBS CyberSecurity’s point is sensible, and it lands because this is no longer a niche tech habit. Pew Research Center says 49% of U.S. adults use AI chatbots, up from roughly one-third in 2024. That kind of adoption curve...

Continue Reading
DocLinq Takes Aim at Care Gaps Between Office Visits

Updated Category News Views 223

Healthcare's most expensive loose ends often pile up after the appointment ends. DocLinq, launched from Columbia, Maryland, is taking a run at that awkward stretch between office visits, where records sit in separate systems, chronic-care follow-up gets uneven, and patients are expected to remember far more than any human reasonably can. This is not a story about AI...

Continue Reading
LGT Middle East Win Highlights Patient Private Banking

Updated Category News Views 20

A trophy in Dubai is not a balance sheet, but it can be a useful calling card when the clientele measures relationships in decades rather than quarters. LGT Middle East was named Best Pure Play Private Bank at the WealthBriefing MENA Awards 2026, at a ceremony held in Dubai on November 18. For a family-owned wealth manager working with Middle Eastern families, that sort...

Continue Reading
T. Rowe Price Expands Teams Across 12 Fund Strategies

Updated Category News Views 0

A Quiet Personnel Shift With Real Stakes Twelve strategy changes may sound like administrative wallpaper, but asset managers live and die by who makes the calls. T. Rowe Price is broadening portfolio-management teams across equity and fixed-income offerings while insisting that each strategy's philosophy, process, and risk limits remain intact. Fine. That is the stated...

Continue Reading
CustomerInsights.AI Fast 500 Nod Tests Its AI Model

Updated Category News Views 0

Pharma’s analytics mess is exactly where CustomerInsights.AI has chosen to make its stand. The Scottsdale company’s inclusion in Deloitte’s 2026 Technology Fast 500, announced November 19, is a useful signal that its pitch is finding buyers: life-sciences businesses want AI to do actual commercial work, not sit in a lab demo collecting dust. Still, a Fast 500 badge...

Continue Reading
Blue Diamond's $1 Billion Brand Meets Farm Realities

Updated Category News Views 118

A Ten-Cent Signal Carries Real Weight A ten-cent edge over the industry benchmark may not excite the cocktail-party crowd, but almond growers notice every penny when fertilizer, power and pest control keep gnawing at the farm gate. Blue Diamond Growers says it delivered payments roughly 10 cents above the benchmark in its latest year, alongside net profit that came in...

Continue Reading
MSD's AI Drug Bet Has Promise, but Plenty to Prove

Updated Category News Views 40

A promising molecule remains a very expensive guess until biology agrees. That is the sober lens for MSD's newly announced research collaboration with Isomorphic Labs: potentially meaningful science, certainly interesting strategic positioning, and absolutely no reason yet to start penciling in product sales. One Oncology Target, Not a Finished Drug On November 19, 2026,...

Continue Reading
ROBOTERA Puts Humanoid Robots Into Logistics Night Work

Updated Category News Views 0

Midnight warehouse work is where a humanoid robot has to quit posing and earn its keep. ROBOTERA arrived at the 2026 APEC CEO Summit with a useful answer to the usual shiny-robot nonsense: it says its machines are already working in logistics centers, handling parcel induction and taking on repetitive, physically demanding shifts that people understandably do not line up...

Continue Reading
Circuit Adds Gabe Klein as Microtransit Expansion Adviser

Updated Category News Views 189

Municipal mobility is a slow, political grind, not a shiny-app contest, and Circuit’s decision to add Gabe Klein to its board looks aimed squarely at that reality. The all-electric microtransit operator has brought aboard somebody who has worked inside the machinery of city government, federal transportation policy, electrification, venture investing, and transportation...

Continue Reading

Top 5 Most Recently Viewed Articles

Clipper Realty Inc. Announces Upcoming Third Quarter Report

Updated Category News Views 40

Clipper Realty Inc. Announces Financial Results Release Clipper Realty Inc. (NYSE: CLPR), a distinguished owner and operator of multifamily residential and commercial properties, is gearing up to share its financial performance for the third quarter of 2024. The report will be disclosed after market hours, providing a comprehensive look at the company's financial health....

Continue Reading
Nvidia's Strategic Moves in China May Boost Stock Value

Updated Category News Views 156

Nvidia's Strategic Moves May Boost Investor Confidence Analyst N. Quinn Bolton has recently reaffirmed his Buy rating on Nvidia (NASDAQ: NVDA) while also increasing the price target from $160 to $200. This optimistic projection suggests significant growth potential for Nvidia's stock as it prepares to re-enter a key market. Resuming Shipments of H20 GPUs Nvidia has...

Continue Reading
Strategic Changes in Boliden's Governance Ahead of 2026 AGM

Updated Category News Views 156

Introduction to Boliden's Governance Changes In a significant move to enhance governance, Boliden AB, a leading metals company, has restructured its Nomination Committee ahead of the upcoming Annual General Meeting (AGM) scheduled for 2026. The new framework emphasizes a collaborative approach by involving the company's largest shareholders, ensuring their voices are...

Continue Reading
Influence of Peter Thiel and Elon Musk on Governance

Updated Category News Views 1523

The Influence of Peter Thiel and Elon Musk on Governance The billionaire entrepreneur Peter Thiel wields considerable influence despite not holding an official position within the government. His affiliations with a variety of organizations committed to government reform have led him to be an important figure in contemporary political discourse. Connections to the Trump...

Continue Reading
Biden Administration's Import Regulations Impact E-Commerce Stocks

Updated Category News Views 102

Concerns About New Import Regulations Shares of major Chinese e-commerce companies, such as JD.com (NASDAQ: JD), Alibaba (NYSE: BABA), and Pinduoduo (NASDAQ: PDD), saw a noticeable drop in premarket trading. This decline followed a report suggesting that the Biden administration plans to toughen regulations on low-value imports. Effects on Key Players in E-Commerce...

Continue Reading